Reiterating guidance often stabilizes investor confidence, especially when projections are in line with or exceed analyst estimates. Halozyme's reaffirmation of its FY24 revenue and EPS forecasts, which closely align with analyst expectations, is likely to have a positive short-term impact on its stock price. This is because it signals management's confidence in the company's financial health and growth trajectory.